Artemisinin Partial Resistance Mutations in Zanzibar and Tanzania Suggest Regional Spread and African Origins, 2023

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This project was funded by the National Institutes for Allergy and Infectious Diseases (R01AI155730 to JJJ, JTL and BEN; K24AI134990 to JJJ; F30AI183592 to SVC).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the institutional review board (IRB) in Zanzibar (ZAHREC/01/EXT/July/2023/03), at MUHAS (MUHAS-REC-02-2024-1168), and at UNC (21-1966). Written informed consent, parental consent and/or assent were provided by all participants.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes